COCHLEAR LTD ADR 1/2/O.N. (OC50) - Net Assets
Based on the latest financial reports, COCHLEAR LTD ADR 1/2/O.N. (OC50) has net assets worth €1.95 Billion EUR (≈ $2.28 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.83 Billion ≈ $3.30 Billion USD) and total liabilities (€874.70 Million ≈ $1.02 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OC50 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.95 Billion |
| % of Total Assets | 69.04% |
| Annual Growth Rate | 4.98% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 0.93 |
COCHLEAR LTD ADR 1/2/O.N. - Net Assets Trend (2022–2025)
This chart illustrates how COCHLEAR LTD ADR 1/2/O.N.'s net assets have evolved over time, based on quarterly financial data. Explore investment intensity of COCHLEAR LTD ADR 1/2/O.N. to see how much of total assets are deployed in long-term investments.
Annual Net Assets for COCHLEAR LTD ADR 1/2/O.N. (2022–2025)
The table below shows the annual net assets of COCHLEAR LTD ADR 1/2/O.N. from 2022 to 2025. For live valuation and market cap data, see OC50 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €1.95 Billion ≈ $2.28 Billion |
+5.97% |
| 2024-06-30 | €1.84 Billion ≈ $2.15 Billion |
+5.24% |
| 2023-06-30 | €1.75 Billion ≈ $2.04 Billion |
+3.74% |
| 2022-06-30 | €1.69 Billion ≈ $1.97 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to COCHLEAR LTD ADR 1/2/O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 70.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €777.30 Million | 39.86% |
| Other Components | €1.17 Billion | 60.14% |
| Total Equity | €1.95 Billion | 100.00% |
COCHLEAR LTD ADR 1/2/O.N. Competitors by Market Cap
The table below lists competitors of COCHLEAR LTD ADR 1/2/O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RioCan Real Estate Investment Trust
TO:REI-UN
|
$4.66 Billion |
|
Boot Barn Holdings Inc
NYSE:BOOT
|
$4.66 Billion |
|
Hangzhou Binjiang Real Estate Group Co Ltd
SHE:002244
|
$4.66 Billion |
|
AutoStore Holdings Ltd
OL:AUTO
|
$4.67 Billion |
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
$4.65 Billion |
|
Ondas Holdings Inc.
NASDAQ:ONDS
|
$4.64 Billion |
|
Spirit Aerosystems Holdings Inc
NYSE:SPR
|
$4.64 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
$4.64 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COCHLEAR LTD ADR 1/2/O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,840,500,000 to 1,950,300,000, a change of 109,800,000 (6.0%).
- Net income of 388,900,000 contributed positively to equity growth.
- Dividend payments of 278,200,000 reduced retained earnings.
- Share repurchases of 28,300,000 reduced equity.
- New share issuances of 100,000 increased equity.
- Other factors increased equity by 27,300,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €388.90 Million | +19.94% |
| Dividends Paid | €278.20 Million | -14.26% |
| Share Repurchases | €28.30 Million | -1.45% |
| Share Issuances | €100.00K | +0.01% |
| Other Changes | €27.30 Million | +1.4% |
| Total Change | €- | 5.97% |
Book Value vs Market Value Analysis
This analysis compares COCHLEAR LTD ADR 1/2/O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.19x to 1.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €25.63 | €30.40 | x |
| 2023-06-30 | €26.62 | €30.40 | x |
| 2024-06-30 | €28.10 | €30.40 | x |
| 2025-06-30 | €29.82 | €30.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently COCHLEAR LTD ADR 1/2/O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.94%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.60%
- • Asset Turnover: 0.83x
- • Equity Multiplier: 1.45x
- Recent ROE (19.94%) is above the historical average (18.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 17.15% | 17.54% | 0.67x | 1.46x | €120.53 Million |
| 2023 | 17.19% | 15.53% | 0.75x | 1.47x | €125.72 Million |
| 2024 | 19.39% | 15.96% | 0.81x | 1.49x | €172.75 Million |
| 2025 | 19.94% | 16.60% | 0.83x | 1.45x | €193.87 Million |
Industry Comparison
This section compares COCHLEAR LTD ADR 1/2/O.N.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $37,411,546,005
- Average return on equity (ROE) among peers: -877.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COCHLEAR LTD ADR 1/2/O.N. (OC50) | €1.95 Billion | 17.15% | 0.45x | $4.65 Billion |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.50 Billion | 7.19% | 0.43x | $146.67K |
| BIORETEC OY (0TN) | $9.74 Million | -47.38% | 0.18x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $349.05 Billion | 12.63% | 0.39x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $76.93K | -8590.94% | 35.29x | $28.30 Million |
| Medtronic PLC (2M6) | $1.75 Billion | 30.35% | 0.38x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $2.64 Billion | -15.46% | 0.26x | $391.36 Million |
| AVITA Medical Inc (51KB) | $20.86 Million | -118.03% | 0.23x | $172.49 Million |
| BRAINCOOL AB (5YL) | $111.74 Million | -54.84% | 0.19x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About COCHLEAR LTD ADR 1/2/O.N.
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor… Read more